. 2019 Aug 28;2(8):e1910154. doi: 10.1001/jamanetworkopen.2019.10154

Table 1. Study Characteristics^a.

Source	Country	Study Duration	Total Participants Recruited, No./Total in Analysis, No.	Age, Mean (SD), y	Time Since Menopause, Mean (SD), y	HT			Amount of Physical Activity, Mean (SD)
Source	Country	Study Duration	Total Participants Recruited, No./Total in Analysis, No.	Age, Mean (SD), y	Time Since Menopause, Mean (SD), y	Type	Dosage, mg/d	Follow-up Period/Duration of HT	Amount of Physical Activity, Mean (SD)
Aloia et al,⁶⁰ 1995	United States	NA	118/77	52.162 (5.7)	2.27 (0.33)	E-P	E: 0.625	E: 25 d/mo	None reported
Aloia et al,⁶⁰ 1995	United States	NA	118/77	52.162 (5.7)	2.27 (0.33)	E-P	P: 10	P: 9 d (days 16-25)	None reported
Bea et al,⁴⁶ 2011	United States	1993-2004	1)^a 927/927	1) 63.35 (7.6)	1) 22.21 (8.4)	1) E	0.625	7.7 (1.8) y	E: 10.1 (12.8)^b
			1)^a 927/927	1) 63.35 (7.6)	1) 22.21 (8.4)	1) E	0.625	7.7 (1.8) y	Control: 9.3 (11.4)^c
			2) 1014/1014	2) 63.29 (7.2)	2) 13.53 (8.5)	2) E-P	E: 0.625	6.3 (1.5) y	E: 11.4 (14.6)
			2) 1014/1014	2) 63.29 (7.2)	2) 13.53 (8.5)	2) E-P	P: 2.5	6.3 (1.5) y	Control: 11.9 (14.6)
Blackman et al,⁴⁷ 2002	United States	1992-1998	28/28	71.5 (5.9)	NA	E-P	E: 100 for 6 mo	E: 6 mo	None reported
Blackman et al,⁴⁷ 2002	United States	1992-1998	28/28	71.5 (5.9)	NA	E-P	P: 10 for the last 10 d of each 28-d cycle	P: last 10 d of each 28-d cycle for 6 mo (approximately 60-65 d)	None reported
Chen et al,⁵⁷ 2005	United States	1993-2001	835/835; Sensitivity analysis: 511/256 (placebo arm), 511/255 (treatment arm)	63.1 (7.2)	13.8 (8.9)	E-P	E: 0.625	3 y	None reported
Chen et al,⁵⁷ 2005	United States	1993-2001		63.1 (7.2)	13.8 (8.9)	E-P	P: 2.5	3 y	None reported
Evans et al,⁶¹ 2001	United States	NA	68/68 (But only 34 in HT and placebo groups combined)	67.7 (5.2)	Mean (SD) age at menopause: 49 (5) y; current mean (SD) age: 67.8 (5) y	E-P	E: 0.625	13 d every third month	None reported
Evans et al,⁶¹ 2001	United States	NA	68/68 (But only 34 in HT and placebo groups combined)	67.7 (5.2)		E-P	P: 5	13 d every third month	None reported
Haarbo et al,⁴⁸ 1991	Denmark	NA	75/62 (19 HT)	45-55	20.9 (8.4) mo	1) E-P	E: 2	2 y	None reported
			75/62 (19 HT)		20.9 (8.4) mo	1) E-P	P: 1	2 y
			75/62 (19 HT)		22.4 (9.9) mo	2) E-P	E: 2	2 y
			75/62 (19 HT)		22.4 (9.9) mo	2) E-P	P: 75	2 y
Hassager and Christiansen,⁵⁸ 1989	Denmark	1983-1985	133/65	1) 49.91 (2.36)	Inclusion criteria: menopause within the past 0.5-3.0	1) E-P (oral)	E: 2	In a 28-d cycle: E: days 1-11	None reported
							P:	E-P: days 12-21
							P:	None: days 22-28
			133/45	2) 50.41 (2.29)		2) E (percutaneous)	E: 0.6	In a 28-d cycle:
								E: days 1-24, 5 g
								None: days 25-28
Jensen et al,⁴⁹ 2003^d	Denmark	1990-1993	1006/621	50.1 ( 2.8)	0.7 (0.6) y	1) E	2	5 y	E: 0.98 (13.02)^e
						2) E-P	E: 2	In a 28 d cycle:	E: 0.98 (13.02)^e
							P: 1	E: days 1-12	Control: 1.187 (12.66)
								E-P: days 13-22 E: days 23-28	Control: 1.187 (12.66)
Kenny et al,⁵⁰ 2005	United States	NA	167/107	74.3 (6.2)	Mean (SD) age: 74.3 (0.6)	E	0.25 (Ultralow dose)	36 mo	E: Baseline: 120.9 (6.2)^f
									36 mo: 104.8 (6.6)
									Placebo: baseline: 99.8 (6.1)
									36 mo: 84.7 (6.9)
Pöllänen et al,⁵¹ 2007	Finland	NA	20/15	53.6 (1.85)	2.8 (3.6)	E-P	E: 2	1 y	None reported
Pöllänen et al,⁵¹ 2007	Finland	NA	20/15	53.6 (1.85)	2.8 (3.6)	E-P	P: 1	1 y	None reported
Sipilä et al,⁵² 2001	Finland	NA	80/52 (30 in HT and placebo groups combined)	50-55	Inclusion criteria: menopause within the past 5 y	E-P	E: 2	1 y	None reported
Sipilä et al,⁵² 2001	Finland	NA	80/52 (30 in HT and placebo groups combined)	50-55	Inclusion criteria: menopause within the past 5 y	E-P	P: 1	1 y	None reported
Sørensen et al,⁵⁹ 2001	Denmark	NA	16/14	55.5 (2.6)	5.9 (3.9)	E-P	E: 4	In a 28-d cycle; follow-up/duration not specified	None reported
Sørensen et al,⁵⁹ 2001	Denmark	NA	16/14	55.5 (2.6)	5.9 (3.9)	E-P	P: 1	E: 4 mg for 22 d and 1 mg for 6 d; P: 10 d; total: 12 wk	None reported
Thorneycroft et al,⁵³ 2007	United States	NA	822/502	51.9 (3.3)	2.2 (0.9)	1) E	1A) E: 0.625	2 y	None reported
				51.5 (4.1)	2.2 (0.9)		1B) E: 0.45	2 y
				52.0 (3.7)	2.5 (1.0)		1C) E: 0.3	2 y
				51.5 (3.8)	2.5 (0.9)	2) E-P	1A) E: 0.625	2 y
				51.5 (3.8)	2.5 (0.9)		P: 2.5	2 y
				51.1 (3.5)	2.3 (0.9)		1B) E: 0.45	2 y
				51.1 (3.5)	2.3 (0.9)		P: 2.5	2 y
				52.3 (3.9)	2.3 (1.0)		1C) E: 0.45	2 y
				52.3 (3.9)	2.3 (1.0)		P: 1.5	2 y
				51.3 (3.5)	2.3 (1.0)		1D) E: 0.3	2 y
				51.3 (3.5)	2.3 (1.0)		P: 1.5	2 y

Abbreviations: E, estrogen therapy; E-P, estrogen plus progesterone therapy; HT, hormone therapy; NA, not available or not reported; P, progesterone therapy; SE, standard error.

^{^a}

Numbering refers to treatment group.

^{^b}

Mean (SD) of baseline weekly energy expenditure (metabolic equivalent values).

^{^c}

Control groups may have included women receiving placebo or women not receiving HT at all.

^{^d}

For the meta-analysis, both treatment arms from Jensen et al⁴⁹ have been combined. The study did not provide separate lean body mass measures for treatment arms 1 and 2.

^{^e}

Mean (SD) of change in amount of exercise (hours per week) across course of study.

^{^f}

Mean (SE) of total baseline Physical Activity Scale for the Elderly (PASE) score. The PASE is a 5-minute, easily scored survey designed specifically to assess physical activity in epidemiological studies of persons aged 65 years and older. It is self-rated, scores range from 0 to 793, and higher scores indicate greater physical activity.⁷²

Table 1. Study Characteristicsa.

Table 1. Study Characteristics^a.